Welcome to our dedicated page for DexCom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on DexCom stock.
DexCom, Inc. (DXCM) is a leading medical device company founded in 1999, specializing in continuous glucose monitoring (CGM) systems. These systems provide a significant advancement over traditional blood glucose meters, offering real-time glucose readings for diabetic patients. DexCom's innovative CGM technology empowers patients and clinicians to better manage diabetes, contributing to improved health outcomes.
DexCom's flagship products include the Dexcom G6 and the newly developed Dexcom G7 CGM systems. These devices offer features such as customizable alerts, seamless app integration, and data sharing capabilities. The company is also working on integrating their CGM systems with insulin pumps from Insulet and Tandem Diabetes Care, Inc., enabling automatic insulin delivery for more efficient diabetes management.
Recent achievements include the expansion into international markets and the continuous enhancement of their product lineup through research and development. Financially, DexCom has shown robust growth with increasing revenues and solid market performance, reflecting the growing demand for advanced diabetes management solutions.
The company has established strategic partnerships with key players in the medical device industry, further enhancing their market presence and technological capabilities. DexCom is committed to innovation, patient empowerment, and improving the quality of life for people with diabetes worldwide.
Dexcom and Tandem Diabetes Care support Canadian athlete Sébastien Sasseville in his 14-day cycling challenge across Canada to raise awareness for diabetes technology access. The endeavor aims to highlight disparities in access to continuous glucose monitoring (CGM) systems across provinces. Recent announcements regarding public coverage of CGM systems in Quebec, Saskatchewan, and British Columbia reflect progress, yet inequalities persist. Sasseville uses the t:slim X2 insulin pump and Dexcom G6 CGM to manage his type 1 diabetes during the ride.
Dexcom (NASDAQ: DXCM) announces expanded provincial coverage for the Dexcom G6 CGM System through BC PharmaCare for individuals aged two years and older on intensive insulin therapy. This initiative aims to enhance diabetes management, providing broader access to life-changing technology. Notable endorsements from medical professionals highlight the positive impact of CGM on glycemic control and reduction in emergency room visits due to severe hypoglycemia. BC now joins other provinces in Canada offering public coverage for CGM systems.
DexCom (Nasdaq: DXCM) has unveiled findings from two studies presented at the 14th International Conference on Advanced Technologies & Treatments for Diabetes. The MOBILE study indicates significant benefits of continuous glucose monitoring (CGM) for Type 2 diabetes patients using basal insulin. Key outcomes include increased time in optimal glucose range and significant A1c reduction. Additionally, new data on the Dexcom G7 shows promising sensor accuracy. These advancements highlight DexCom’s ongoing commitment to enhancing diabetes care.
DexCom (NASDAQ:DXCM) has announced an upcoming presentation at the William Blair 41st Annual Growth Stock Conference. Jereme Sylvain, Executive Vice President and CFO, will represent the company on June 1, 2021, at 12:00pm CDT. The presentation will be available via live webcast on the Dexcom Investor Relations website, where it will also be archived for future reference.
DexCom empowers individuals to manage diabetes through cutting-edge continuous glucose monitoring (CGM) technology, enhancing diabetes care globally.
DexCom reported a robust Q1 2021 with revenue of $505 million, up 25% year-over-year. U.S. revenue grew by 30% while international revenue rose by 10%. GAAP operating income reached $45.9 million (9.1% of revenue), an increase of 80 basis points from last year. Despite a decrease in non-GAAP operating margin, the company has expanded its U.S. sales force and launched a venture capital fund. DexCom has raised its 2021 revenue guidance to $2.26 - 2.36 billion, anticipating 17-22% growth.
DexCom, Inc. (NASDAQ:DXCM) will release its first quarter 2021 financial results on April 29, 2021, after market close. A conference call is scheduled for 4:30 p.m. (Eastern Time) the same day to discuss the results, which will also be available via webcast on the company's investor relations website. DexCom is recognized for its innovative continuous glucose monitoring (CGM) systems, aiming to enhance diabetes management worldwide.
DexCom, Inc. (NASDAQ: DXCM) has announced the promotion of Jereme Sylvain to Executive Vice President and Chief Financial Officer. Sylvain, who has over 20 years of experience in corporate finance, previously served as Senior Vice President, Finance and Chief Accounting Officer since March 2020. His new role includes overseeing the entire finance organization and supporting COO Quentin Blackford in scaling the business and corporate development efforts. CEO Kevin Sayer highlighted Sylvain's contributions to the finance team and the company's growth strategy.
DexCom (NASDAQ:DXCM) will present updates at three upcoming virtual investor conferences. Quentin Blackford, COO and CFO, will speak at the Citi Healthcare Conference on February 24, 2021, at 1:30 PM (EST). Jereme Sylvain, SVP of Finance, will present on February 25, 2021, at the SVB Leerink Global Healthcare Conference at 3:40 PM (EST) and again on March 1, 2021, at the Raymond James Institutional Investors Conference at 10:50 AM (EST). Webcasts will be available on the Dexcom Investor Relations website for future reference.
DexCom (Nasdaq: DXCM) has launched Dexcom Ventures, aiming to invest in innovative technologies that enhance its core diabetes monitoring business. The fund, led by Steve Pacelli, will focus on sensing technology, data analytics, and remote patient monitoring. CEO Kevin Sayer states that this move accelerates growth opportunities and supports developments in glucose sensing and metabolic monitoring. Dexcom Ventures marks the company's entry into venture capital, emphasizing its commitment to strategic investments to improve healthcare outcomes.
DexCom reported strong financial results for Q4 and the fiscal year ended December 31, 2020. Q4 revenue reached $568.9 million, a 23% increase year-over-year, while full-year revenue grew 31% to $1.93 billion. Operating income for Q4 was $104.0 million, with a GAAP operating margin of 18.3%. The company announced a strategic expansion of its sales force and secured reimbursement for its G6 CGM system in France. For 2021, DexCom projects revenue between $2.21 billion and $2.31 billion, indicating 15-20% growth.
FAQ
What is the current stock price of DexCom (DXCM)?
What is the market cap of DexCom (DXCM)?
What does DexCom, Inc. specialize in?
When was DexCom, Inc. founded?
What are some of DexCom's key products?
How do DexCom's CGM systems benefit diabetic patients?
What recent achievements has DexCom made?
How is DexCom integrating its CGM systems with other technologies?
What is the significance of DexCom's strategic partnerships?
What is DexCom's approach to innovation?
How does DexCom support the community?
What financial trends are seen in DexCom's performance?
